Cyclerion Therapeutics Files 8-K for Material Definitive Agreement
Ticker: CYCN · Form: 8-K · Filed: Sep 23, 2025 · CIK: 1755237
| Field | Detail |
|---|---|
| Company | Cyclerion Therapeutics, Inc. (CYCN) |
| Form Type | 8-K |
| Filed Date | Sep 23, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $4.4 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, 8-k
TL;DR
Cyclerion Therapeutics signed a big deal, filing an 8-K on 9/19/25.
AI Summary
On September 19, 2025, Cyclerion Therapeutics, Inc. entered into a material definitive agreement. The company, headquartered in Cambridge, MA, filed an 8-K report detailing this agreement. Further specifics regarding the nature of the agreement and any associated financial figures are not detailed in the provided excerpt.
Why It Matters
This filing indicates a significant new contract or partnership for Cyclerion Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could carry significant implications, but the lack of detail in the excerpt prevents a precise risk assessment.
Key Numbers
- 001-38787 — SEC File Number (Identifies the company's filing history with the SEC.)
- 83-1895370 — IRS Employer Identification No. (Tax identification number for the company.)
Key Players & Entities
- Cyclerion Therapeutics, Inc. (company) — Registrant
- September 19, 2025 (date) — Date of earliest event reported
- Massachusetts (location) — State of incorporation
- Cambridge, Massachusetts (location) — Address of Principal Executive Offices
FAQ
What is the nature of the material definitive agreement entered into by Cyclerion Therapeutics?
The provided excerpt does not specify the nature of the material definitive agreement.
What is the effective date of the material definitive agreement?
The earliest event reported, which includes the entry into the material definitive agreement, is dated September 19, 2025.
Where is Cyclerion Therapeutics, Inc. headquartered?
Cyclerion Therapeutics, Inc. has its principal executive offices at 245 First Street, 18th Floor, Cambridge, Massachusetts 02142.
What is Cyclerion Therapeutics' SEC file number?
Cyclerion Therapeutics' SEC file number is 001-38787.
What is the company's state of incorporation?
The company is incorporated in Massachusetts.
Filing Stats: 859 words · 3 min read · ~3 pages · Grade level 11.5 · Accepted 2025-09-23 16:14:59
Key Financial Figures
- $4.4 million — d MIT will be eligible to receive up to $4.4 million upon the achievement of certain develop
Filing Documents
- d51498d8k.htm (8-K) — 29KB
- d51498dex991.htm (EX-99.1) — 12KB
- d51498dex992.htm (EX-99.2) — 19KB
- g51498ex99_2p10g1.jpg (GRAPHIC) — 238KB
- g51498ex99_2p11g1.jpg (GRAPHIC) — 225KB
- g51498ex99_2p12g1.jpg (GRAPHIC) — 330KB
- g51498ex99_2p13g1.jpg (GRAPHIC) — 237KB
- g51498ex99_2p14g1.jpg (GRAPHIC) — 159KB
- g51498ex99_2p15g1.jpg (GRAPHIC) — 117KB
- g51498ex99_2p1g1.jpg (GRAPHIC) — 178KB
- g51498ex99_2p2g1.jpg (GRAPHIC) — 419KB
- g51498ex99_2p3g1.jpg (GRAPHIC) — 283KB
- g51498ex99_2p4g1.jpg (GRAPHIC) — 337KB
- g51498ex99_2p5g1.jpg (GRAPHIC) — 393KB
- g51498ex99_2p6g1.jpg (GRAPHIC) — 253KB
- g51498ex99_2p7g1.jpg (GRAPHIC) — 220KB
- g51498ex99_2p8g1.jpg (GRAPHIC) — 257KB
- g51498ex99_2p9g1.jpg (GRAPHIC) — 205KB
- g51498g0923192152470.jpg (GRAPHIC) — 3KB
- g51498g0923192152550.jpg (GRAPHIC) — 3KB
- 0001193125-25-213332.txt ( ) — 5501KB
- cycn-20250919.xsd (EX-101.SCH) — 3KB
- cycn-20250919_lab.xml (EX-101.LAB) — 18KB
- cycn-20250919_pre.xml (EX-101.PRE) — 11KB
- d51498d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated September 23, 2025 99.2 Investor Presentation, dated September 24, 2025. 104 Cover Page Interactive Data File (formatted as Inline XBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CYCLERION THERAPEUTICS, INC. Date: September 23, 2025 By: /s/ Regina Graul, Ph.D. Name: Regina Graul, Ph.D. Title: President and Chief Executive Officer